Stifel analyst Paul Matteis reiterated a Buy rating and $123.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst commented, "In ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE